Experts find several treatments effective in SM-related osteoporosis
Zoledronic acid, bisphosphonates, IFN-alpha and denosumab appear to prevent fractures and increase BMD in SM patients with osteoporosis.
Zoledronic acid, bisphosphonates, IFN-alpha and denosumab appear to prevent fractures and increase BMD in SM patients with osteoporosis.
Lipid-lowering medications (LLMs) may increase the risk of severe anaphylactic reactions, which would greatly affect patients with SM.
Indolent systemic mastocytosis (ISM) appears to significantly affect activities of daily living in over 50% of patients.
A new study detailed cellular and other changes resulting from avapritinib therapy for systemic mastocytosis.
The cellular marker CD30 appears to play a key role in cutaneous mastocytosis, which differs from systemic mastocytosis, a new study says.
Patients with mast cell activation syndrome (MCAS) could require annual controls to detect potential progression to systemic mastocytosis.
A new case study reported promising results for a man who started experimental therapy for SM symptoms after other treatment failed.
Increased awareness and diagnosis of SM could increase the growth of the SM pharmaceutical market by 2034.
A recent study assessed the current state of treatments for advanced systemic mastocytosis and the promise of future ones.
A new study detailed a rare case of a man with systemic mastocytosis who presented with symptoms of osteoporosis.